Improving the convenience and ease of administration of parenteral therapeutics has become a common strategy adopted by biotechnology and pharmaceutical industries and is expected to drive growth of injection pen market. Key players aim to introduce novel drug delivery system by targeting end-user flexibility such as fewer handling steps, higher volumes, thinner needles, high viscous formulations, and novel primary containers to accommodate changing injection pen market trends.
For instance, in 2015, Antares Pharma launched Makena subcutaneous auto injector in collaboration with AMAG Pharmaceuticals. This collaboration clubs hydroxyprogesterone caproate injection of Antares Pharma that is used to reduce the risk of preterm birth in women pregnant with a single baby who has a history of singleton spontaneous preterm birth, with QuickShot auto-injector of AMAG Pharmaceuticals to allow rapid subcutaneous self-administration of highly viscous drugs in oil such as testosterone or progesterone and biologics using high spring pressure through a fine gauge needle.
The prevalence of chronic diseases is increasing due to rapid aging of the population and the greater longevity of people with chronic conditions such as diabetes, multiple sclerosis (MS), rheumatoid arthritis (RA), hepatitis, osteoporosis, hemophilia, reproductive health, anemia, hemolytic disease, and anti-thrombolytic therapy. Injection pen market was predominant in diabetes therapy and growth hormone therapy for the past 20 years and 10 years respectively due to disease prevalence. According to the American Diabetes Association, in 2015, 9.4 % of the people in the U.S. suffered from diabetes while 1.5 million people were diagnosed with diabetes every year. This suggests predominance of injection pen market for diabetes therapy. Moreover, recent advancements widens application of injection pen for reproductive health, osteoporosis, and hepatitis.
Download the PDF brochure:
Furthermore, manufacturers of injection pens are focusing on device advancements or company pipeline to meet the requirements of next-generation molecules and anticipated end-user needs. For instance, Biocorp launched Datapen and Easylog, two internet connected devices in 2015. Additional features of Datapen and Easylog device includes dose setup setting, Oled display, audio as well as visual signals to guide patients, and real time transfer of treatment information to storage platform and mobile app. Furthermore, increasing pipeline product will lead to expansion of therapeutic options for medical practitioners as well as for patients, thereby propelling growth of injection pen market.
Injection Pen Market – Regional Analysis
On the basis of region, the global injection pen market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the global injection pen market, owing to increasing product advancements by the key players in the region, whereas Asia Pacific is expected to be the fastest growing market over the forecast period due to increasing population size and increasing development of healthcare amenities.
Injection Pen Market – Competitor Analysis
The injection pen market is mainly led by 3 companies: Novo Nordisk, Sanofi, and ELI Lilly and Company. Other major players in the injection pen market include Merck & co., Inc., Ypsomed holding AG, Biocorp Production SA, AstraZeneca PLC, F.Hoffman-La Roche Ltd, Becton, Dickinson and Company (BD), Owen Mumford Ltd, Novartis, Pfizer, and Wilhelm Haselmeier GmbH & Co. KG.
Get HOLISTIC Request Sample Copy Of This Business Report:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154